Novo Raises Forecast as Obesity Drug Sales Surge, CEO Backs Cagrisema
WHO:
Bloomberg - Mike Doustdar is chief executive officer of Novo Nordisk A/S.
IJR - Novo Nordisk is the company whose outlook and results were reported.
WHAT:
Yahoo Finance - Novo Nordisk expects 2026 adjusted sales and adjusted operating profit to range from a 2% decline to 2% growth at constant exchange rates, compared with its previous forecast of a 6% decline to flat.
Yahoo Finance - Third-quarter adjusted sales were 79.20 billion Danish crowns, up from 74.98 billion a year earlier; adjusted operating profit rose 27% at constant exchange rates to 31.72 billion crowns from 23.68 billion.
Yahoo Finance - Reported operating profit fell 9% at constant exchange rates to 23.01 billion crowns, reflecting 8.7 billion crowns in non-cash impairment charges: a 4.6 billion-crown write-down related to ziltivekimab and 4.1 billion crowns linked to manufacturing-network restructuring.
Yahoo Finance - Obesity-care sales rose 22% at constant exchange rates to 26.15 billion crowns, driven by volume growth in the United States and international markets.
Yahoo Finance - Adjusted sales exceeded Visible Alpha’s 73.4 billion-crown consensus by 8%; adjusted operating profit exceeded its 28.9 billion-crown consensus by 10%.
Yahoo Finance - Novo plans to cut U.S. wholesale acquisition prices for Wegovy by about 50% and Ozempic by 35%, to $675, effective Jan. 1, 2027.
Bloomberg - Novo Nordisk raised its forecast for the year again.
Bloomberg - Doustdar said the company is “Very Optimistic” about CagriSema, a possible new obesity drug.
Bloomberg - Doustdar said Novo Nordisk was “hopeful that we will be able to get the timely approval from the FDA at the end of this year and launch it at the beginning of next year.”
IJR - Novo Nordisk raised its 2026 outlook after third-quarter revenue and adjusted operating profit beat expectations.
IJR - Obesity-drug sales grew 22%, with Wegovy particularly driving growth.
IJR - Reported profit fell because of impairment charges.
IJR - The company said stronger GLP-1 demand underpinned its improved forecast.
WHERE:
Bloomberg - Doustdar discussed CagriSema on Bloomberg Television.
Bloomberg - The FDA is the agency from which Novo Nordisk is seeking approval for CagriSema.
WHY:
Yahoo Finance - Jefferies said gross-to-net pricing tailwinds of about 2 billion crowns, mainly supporting injectable Wegovy, flattered the sales beat; excluding them, the beat would have been about 5%, and Wegovy would have missed expectations.
Bloomberg - The new Wegovy pill and older Ozempic shot helped buoy earnings, contributing to optimism after the forecast increase.
IJR - Stronger demand for GLP-1 medicines and growth in obesity-drug sales supported Novo Nordisk’s improved outlook.
HOW:
Yahoo Finance - Novo expects 2026 free cash flow of 60 billion to 70 billion crowns, up from its previous forecast of 45 billion to 55 billion crowns.
Bloomberg - Novo Nordisk’s forecast increase followed earnings support from its Wegovy pill and Ozempic injection.
IJR - Novo Nordisk’s improved outlook followed better-than-expected third-quarter revenue and adjusted operating profit.
(UPDATED November 4, 2026 22:04 UTC)
Novo Nordisk raised its 2026 outlook after third-quarter adjusted sales and operating profit beat expectations. Obesity-drug sales grew 22%, led by Wegovy demand. Impairment charges dragged reported operating profit lower.
--
(UPDATED November 4, 2026 12:02 UTC)
Novo Nordisk raised its forecast after third-quarter revenue and adjusted operating profit beat expectations. Obesity-drug sales grew 22%, with Wegovy and stronger GLP-1 demand supporting growth. CEO Mike Doustdar expressed optimism about CagriSema, a potential obesity drug awaiting FDA approval.